Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:5409 |
Name | lung small cell carcinoma |
Definition | A lung carcinoma that has_material_basis_in primitive-appearing cells that are smaller than normal cells and is located_in the lung. |
Source | DiseaseOntology.org |
Alt Ids | DOID:0050875 |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung small cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 inact mut | APR-246 | lung small cell carcinoma | sensitive | detail... |
RET wild-type | Vandetanib | lung small cell carcinoma | sensitive | detail... |
RET M918T | Ponatinib | lung small cell carcinoma | sensitive | detail... |
RET wild-type | Ponatinib | lung small cell carcinoma | sensitive | detail... |
RET M918T | Vandetanib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | Debio 1347 | lung small cell carcinoma | sensitive | detail... |
TP53 Y163C | APR-246 + Cisplatin | lung small cell carcinoma | sensitive | detail... |
RB1 loss | Trilaciclib | lung small cell carcinoma | resistant | detail... |
RB1 loss | Topotecan + Trilaciclib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | AZD4547 | lung small cell carcinoma | sensitive | detail... |
PIK3CA act mut | Navitoclax + Pictilisib | lung small cell carcinoma | predicted - sensitive | detail... |
TP53 S241F | APR-246 | lung small cell carcinoma | sensitive | detail... |
TP53 R273L | APR-246 | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | RO4987655 | lung small cell carcinoma | no benefit | detail... |
FGFR1 amp | RO5126766 | lung small cell carcinoma | no benefit | detail... |
FGFR1 amp | Selumetinib | lung small cell carcinoma | no benefit | detail... |
FGFR1 rearrange | AZD4547 | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | E7090 | lung small cell carcinoma | sensitive | detail... |
ALK rearrange RB1 C706F TP53 loss | Lorlatinib | lung small cell carcinoma | predicted - resistant | detail... |
FGFR1 amp | AZD4547 + Buparlisib | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | GSK3052230 | lung small cell carcinoma | sensitive | detail... |
FGFR1 amp | Cisplatin + Etoposide + GSK3052230 | lung small cell carcinoma | sensitive | detail... |
CHEK1 over exp | PF-00477736 | lung small cell carcinoma | sensitive | detail... |
CHEK1 over exp | Berzosertib | lung small cell carcinoma | sensitive | detail... |
ATM D2725G | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
ATM S333F | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
ATM V410A | Temozolomide + Veliparib | lung small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Alectinib + Irinotecan | lung small cell carcinoma | predicted - sensitive | detail... |
TP53 Y220C | PC14586 | lung small cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00926640 | Phase I | Belinostat + Cisplatin + Etoposide | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | Completed | USA | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Active, not recruiting | USA | 0 |
NCT01450761 | Phase III | Cisplatin Ipilimumab Carboplatin Etoposide | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 24 |
NCT01579929 | Phase I | Cisplatin + Etoposide + Sonidegib | Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Completed | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | GBR | FRA | ESP | AUS | 2 |
NCT01638546 | Phase II | Temozolomide Veliparib | Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | Completed | USA | 0 |
NCT01642251 | Phase Ib/II | Cisplatin + Etoposide Veliparib | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01722292 | Phase Ib/II | Taladegib Carboplatin + Etoposide | A Study of LY2940680 in Small Cell Lung Cancer | Terminated | USA | GBR | 0 |
NCT01737502 | Phase Ib/II | Auranofin + Sirolimus | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | ESP | 1 |
NCT01859741 | Phase Ib/II | Cisplatin Etoposide Carboplatin Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) | Terminated | USA | 0 |
NCT01892046 | Phase I | Carboplatin SNX-5422 Paclitaxel | Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | Completed | USA | 0 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | GBR | ESP | DEU | CAN | 2 |
NCT02034123 | Phase I | GSK2879552 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | Terminated | USA | FRA | ESP | 0 |
NCT02038647 | Phase II | Paclitaxel Alisertib | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 3 |
NCT02100007 | Phase Ib/II | ME-344 + Topotecan | ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors | Terminated | USA | GBR | 0 |
NCT02152059 | Phase II | Nintedanib | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | Withdrawn | CAN | 0 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | GBR | 0 |
NCT02161419 | Phase II | Roniciclib | RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer | Terminated | USA | ITA | FRA | DEU | BEL | 4 |
NCT02200757 | Phase II | Aldoxorubicin Topotecan | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | Unknown status | USA | ESP | 1 |
NCT02247349 | Phase Ib/II | BMS-986012 BMS-986012 + Nivolumab | BMS-986012 in Relapsed/Refractory SCLC | Completed | USA | CAN | BEL | AUS | 3 |
NCT02250885 | Phase II | Selinexor | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Completed | USA | 0 |
NCT02261805 | Phase Ib/II | Aldoxorubicin + Ganetespib | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | Terminated | USA | 0 |
NCT02289690 | Phase I | Carboplatin + Etoposide + Veliparib | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | Completed | USA | FRA | ESP | CAN | BEL | AUS | 6 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02351505 | Phase II | Selinexor | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02359019 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy | Completed | USA | 0 |
NCT02402920 | Phase I | Carboplatin + Etoposide + Pembrolizumab Cisplatin | Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Completed | USA | FRA | ESP | CAN | AUS | 0 |
NCT02446704 | Phase Ib/II | Olaparib Temozolomide | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | Active, not recruiting | USA | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | 2 |
NCT02472977 | Phase Ib/II | Nivolumab Ulocuplumab | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | Terminated | USA | 1 |
NCT02481830 | Phase III | Amrubicin Nivolumab Topotecan | Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 16 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02489903 | Phase II | Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel | RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens | Completed | USA | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02499770 | Phase Ib/II | Carboplatin + Etoposide Trilaciclib | G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | Completed | USA | FRA | ESP | 4 |
NCT02514447 | Phase Ib/II | Trilaciclib Topotecan | Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | Terminated | USA | BEL | 6 |
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Completed | USA | FRA | ESP | DEU | BEL | 1 |
NCT02537418 | Phase I | Cisplatin + Etoposide Durvalumab Tremelimumab | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens | Active, not recruiting | CAN | 0 |
NCT02538666 | Phase III | Ipilimumab Nivolumab | A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 22 |
NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02579226 | Phase I | Irinotecan AZD2811 | A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ESP | 0 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUS | 12 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02649673 | Phase Ib/II | LCL161 + Topotecan | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | Terminated | USA | 0 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | GBR | FRA | ESP | AUS | 1 |
NCT02671955 | Phase I | JNJ-61610588 | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02674568 | Phase II | Rovalpituzumab Tesirine | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) | Completed | 0 | |
NCT02701400 | Phase II | Tavolimab + Tremelimumab | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | Completed | USA | 0 |
NCT02734004 | Phase Ib/II | Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) | Active, not recruiting | USA | GBR | FRA | 4 |
NCT02735980 | Phase II | Prexasertib | A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer | Completed | USA | GBR | FRA | ESP | DEU | 5 |
NCT02748889 | Phase Ib/II | Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02763579 | Phase III | Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133) | Completed | USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS | 13 |
NCT02815592 | Phase Ib/II | Etoposide BMS-986012 + Cisplatin + Etoposide BMS-986012 + Carboplatin + Etoposide | Trial of BMS-986012 in Combination With Platinum and Etoposide | Active, not recruiting | ESP | 0 |
NCT02819999 | Phase I | Cisplatin + Etoposide + Rovalpituzumab Tesirine Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02874664 | Phase I | Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Active, not recruiting | ITA | GBR | FRA | ESP | 1 |
NCT02899728 | Phase II | Carboplatin + Cisplatin + Etoposide Cediranib + Olaparib | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Recruiting | USA | 0 |
NCT02934503 | Phase II | Carboplatin + Cisplatin + Etoposide + Pembrolizumab | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | Terminated | USA | 0 |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT02963090 | Phase II | Pembrolizumab + Topotecan Pembrolizumab | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Terminated | USA | 0 |
NCT03026166 | Phase I | Ipilimumab + Nivolumab + Rovalpituzumab Tesirine Nivolumab + Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | Terminated | USA | ITA | FRA | ESP | DEU | 0 |
NCT03033511 | Phase III | Dexamethasone + Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 31 |
NCT03041311 | Phase II | Atezolizumab + Carboplatin + Etoposide + Trilaciclib Atezolizumab + Carboplatin + Etoposide | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC) | Terminated | USA | FRA | ESP | 4 |
NCT03043599 | Phase Ib/II | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03043872 | Phase III | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Etoposide Carboplatin + Cisplatin + Etoposide | Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUT | 17 |
NCT03061812 | Phase III | Rovalpituzumab Tesirine Topotecan | Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 24 |
NCT03066778 | Phase III | Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | Completed | USA | GBR | FRA | ESP | DEU | CAN | AUS | 12 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03080311 | Phase I | APG-1252 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | Completed | USA | 0 |
NCT03083691 | Phase II | Ipilimumab + Nivolumab | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | Enrolling by invitation | DEU | 0 |
NCT03085849 | Phase I | Durvalumab + Guadecitabine + Tremelimumab | SGI-110 Plus Durvalumab/Tremelimumab in SCLC | Completed | USA | 0 |
NCT03092934 | Phase Ib/II | LY3295668 | A Study of AK-01 (LY3295668) in Solid Tumors | Completed | CAN | 0 |
NCT03116971 | Phase Ib/II | Cisplatin + Etoposide + Peposertib Peposertib | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | Terminated | USA | ITA | GBR | ESP | DEU | CAN | BEL | 6 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | AUS | 0 |
NCT03179436 | Phase Ib/II | MK-1308 + Pembrolizumab MK-1308 | Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | AUS | 10 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | FRA | ESP | AUS | 6 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT03227016 | Phase I | Topotecan + Veliparib | Study in Patients With SCLC of Veliparib in Combination With Topotecan | Unknown status | DEU | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) | Active, not recruiting | USA | 0 |
NCT03319940 | Phase I | AMG 757 | Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer | Recruiting | USA | GBR | FRA | ESP | DEU | AUT | AUS | 6 |
NCT03325816 | Phase Ib/II | Nivolumab | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | Completed | USA | 0 |
NCT03334487 | Phase III | Dexamethasone + Rovalpituzumab Tesirine | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer | Withdrawn | USA | GBR | DEU | CAN | AUS | 2 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03363893 | Phase Ib/II | ICEC0942 Fulvestrant + ICEC0942 | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Completed | USA | GBR | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03366103 | Phase Ib/II | Navitoclax + Vistusertib | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | Terminated | USA | 0 |
NCT03371979 | Phase Ib/II | Pegzilarginase + Pembrolizumab | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | Completed | USA | 1 |
NCT03382561 | Phase II | Cisplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab Cisplatin + Etoposide Carboplatin + Etoposide | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer | Active, not recruiting | USA | 0 |
NCT03402880 | Phase II | Epacadostat + Pembrolizumab | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03406715 | Phase II | Ad.p53-DC vaccine + Ipilimumab + Nivolumab | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | Terminated | USA | 0 |
NCT03460977 | Phase I | PF-06821497 | PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Recruiting | USA | ESP | 5 |
NCT03467360 | Phase I | Atezolizumab | Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer (ICAR) | Recruiting | FRA | 0 |
NCT03509012 | Phase I | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) | Active, not recruiting | USA | ESP | 3 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03532880 | Phase I | Olaparib | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03554473 | Phase Ib/II | Bintrafusp alfa + Topotecan Bintrafusp alfa + Temozolomide Bintrafusp alfa | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | Recruiting | USA | 0 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03575793 | Phase Ib/II | Ipilimumab + Nivolumab + Plinabulin Ipilimumab + Nivolumab | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | 0 |
NCT03595059 | Phase I | Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | Active, not recruiting | USA | ESP | CAN | AUS | 6 |
NCT03639194 | Phase I | ABBV-011 + Budigalimab ABBV-011 | A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Active, not recruiting | USA | 3 |
NCT03662074 | Phase II | Gemcitabine + Nivolumab | Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer | Completed | USA | 0 |
NCT03670056 | Phase II | Ipilimumab + Nivolumab | A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy | Active, not recruiting | USA | 0 |
NCT03672773 | Phase II | Talazoparib + Temozolomide | Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03703297 | Phase III | Durvalumab Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) | Active, not recruiting | USA | ITA | GBR | ESP | DEU | CAN | BEL | 12 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | USA | FRA | ESP | 3 |
NCT03728361 | Phase II | Nivolumab + Temozolomide | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | Active, not recruiting | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Active, not recruiting | USA | 0 |
NCT03811002 | Phase II | Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide | Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer | Recruiting | USA | 1 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03830918 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | Recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03850067 | Phase Ib/II | Carboplatin + CC-90011 + Etoposide CC-90011 + Cisplatin + Etoposide Nivolumab | A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | Active, not recruiting | ITA | FRA | ESP | 0 |
NCT03879798 | Phase Ib/II | DS-3201b + Irinotecan | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | Completed | USA | 0 |
NCT03896503 | Phase II | Topotecan Berzosertib + Topotecan | Topotecan With or Without M6620 in Treating Patients With Relapsed Small Cell Lung Cancer or Extrapulmonary Small Cell Cancer | Active, not recruiting | USA | 0 |
NCT03898791 | Phase Ib/II | LY3295668 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | Completed | USA | GBR | FRA | ESP | BEL | 3 |
NCT03913455 | Phase II | Carboplatin + Guadecitabine | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03923270 | Phase I | Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03958045 | Phase II | Nivolumab + Rucaparib | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | Active, not recruiting | USA | 0 |
NCT03963414 | Phase I | Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Etoposide | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | Terminated | USA | 0 |
NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Recruiting | USA | FRA | ESP | CAN | BEL | AUS | 2 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT04010357 | Phase II | Abemaciclib | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | Recruiting | USA | 0 |
NCT04022876 | Phase I | ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | Terminated | USA | ITA | ESP | DEU | 3 |
NCT04032704 | Phase II | Ladiratuzumab vedotin | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | AUS | 2 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | Recruiting | USA | AUS | 4 |
NCT04101357 | Phase Ib/II | BNT411 Atezolizumab + BNT411 + Carboplatin + Etoposide | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Recruiting | USA | GBR | ESP | DEU | 0 |
NCT04122625 | Phase Ib/II | Nivolumab + Xevinapant | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Completed | USA | FRA | ESP | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04165330 | Phase Ib/II | Anlotinib + Nivolumab | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | Active, not recruiting | USA | 0 |
NCT04170946 | Phase I | Talazoparib | Talazoparib and Thoracic RT for ES-SCLC | Recruiting | CAN | 0 |
NCT04173325 | Phase I | Nivolumab Irinotecan + Nivolumab | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Terminated | USA | 0 |
NCT04209595 | Phase Ib/II | PLX038 + Rucaparib | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | Active, not recruiting | USA | 0 |
NCT04210037 | Phase Ib/II | APG-1252 + Paclitaxel | Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | Terminated | USA | AUS | 0 |
NCT04221529 | Phase II | Atezolizumab | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide (SPACE) | Recruiting | DEU | AUT | 0 |
NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients | Recruiting | USA | 0 |
NCT04253145 | Phase I | Atezolizumab + Lurbinectedin | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | Unknown status | ESP | 0 |
NCT04256421 | Phase III | Atezolizumab + Carboplatin + Etoposide + Tiragolumab Atezolizumab + Carboplatin + Etoposide | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02) | Active, not recruiting | USA | ITA | GBR | ESP | DEU | BEL | AUT | AUS | 15 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Recruiting | AUS | 1 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) | Recruiting | USA | 0 |
NCT04334941 | Phase II | Atezolizumab + Talazoparib Atezolizumab | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | Active, not recruiting | USA | 0 |
NCT04350463 | Phase II | CC-90011 + Nivolumab | A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | Active, not recruiting | USA | ITA | GBR | FRA | ESP | 1 |
NCT04358237 | Phase Ib/II | Lurbinectedin + Pembrolizumab | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. (LUPER) | Active, not recruiting | ESP | 0 |
NCT04373369 | Phase II | Atezolizumab + Vorolanib | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Recruiting | USA | 9 |
NCT04397003 | Phase II | Carboplatin + Durvalumab + Etoposide Durvalumab + Tremelimumab Durvalumab + Personalized cancer vaccine + Tremelimumab | Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04402788 | Phase II | Atezolizumab Atezolizumab + Radiotherapy | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Recruiting | USA | 0 |
NCT04422210 | Phase I | Atezolizumab + Venetoclax Atezolizumab + Carboplatin + Etoposide + Venetoclax | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). | Terminated | USA | ESP | 2 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04429087 | Phase I | BI 764532 | A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). | Recruiting | USA | ESP | DEU | 1 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Recruiting | AUS | 2 |
NCT04462276 | Phase II | Atezolizumab | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease (TREASURE) | Active, not recruiting | DEU | AUT | 0 |
NCT04471727 | Phase Ib/II | Atezolizumab + HPN328 HPN328 | Study in Patients With Advanced Cancers Associated With Expression of DLL3 | Recruiting | USA | 0 |
NCT04487756 | Phase Ib/II | Atezolizumab + Carboplatin + Etoposide | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer (VENEZO-LUNG) | Recruiting | ESP | 0 |
NCT04491942 | Phase I | BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Recruiting | USA | CAN | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Active, not recruiting | USA | FRA | ESP | CAN | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Recruiting | USA | 0 |
NCT04514497 | Phase I | BAY1895344 + Irinotecan BAY1895344 + Topotecan | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | Recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04538378 | Phase II | Durvalumab + Olaparib | Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors | Recruiting | USA | 0 |
NCT04543916 | Phase Ib/II | Irinotecan + Venetoclax | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | Withdrawn | 0 | |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Recruiting | USA | 3 |
NCT04560972 | Phase I | Atezolizumab + Carboplatin + Etoposide + LB-100 Atezolizumab + LB-100 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04579757 | Phase Ib/II | Surufatinib + Tislelizumab | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04590781 | Phase Ib/II | Pembrolizumab + XmAb18087 XmAb18087 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT04602533 | Phase II | Cisplatin + Etoposide Durvalumab | Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | Recruiting | DEU | 0 |
NCT04607954 | Phase II | Durvalumab + Topotecan | Durvalumab and Topotecan for the Treatment of Relapsed or Refractory Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04610658 | Phase Ib/II | Ipilimumab + Lurbinectedin + Nivolumab | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | Terminated | USA | 0 |
NCT04610684 | Phase II | Atezolizumab Atezolizumab + Carboplatin + Etoposide | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | Active, not recruiting | USA | 0 |
NCT04624204 | Phase III | Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 17 |
NCT04631029 | Phase I | Atezolizumab + Carboplatin + Entinostat + Etoposide Atezolizumab + Entinostat | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | Active, not recruiting | USA | 0 |
NCT04641871 | Phase I | Sym021 + Sym023 Sym021 + Sym022 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | FRA | ESP | CAN | 0 |
NCT04696575 | Phase II | Atezolizumab + Carboplatin + Etoposide + Lamivudine Atezolizumab + Lamivudine | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04699838 | Phase II | Carboplatin + Ceralasertib + Durvalumab + Etoposide Ceralasertib + Cisplatin + Durvalumab + Etoposide | Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04701307 | Phase II | Dostarlimab-gxly + Niraparib | Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas | Active, not recruiting | USA | 0 |
NCT04702880 | Phase II | BMS-986012 + Carboplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | Recruiting | USA | ITA | ESP | CAN | BEL | AUS | 5 |
NCT04728230 | Phase Ib/II | Carboplatin + Durvalumab + Etoposide + Olaparib | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | Recruiting | USA | 0 |
NCT04730999 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Etoposide | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer (CeLEBrATE) | Active, not recruiting | ITA | 0 |
NCT04745689 | Phase II | AZD2811 + Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN) | Active, not recruiting | USA | ESP | 2 |
NCT04768296 | Phase II | Berzosertib + Topotecan | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | 2 |
NCT04774380 | Phase III | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE) | Active, not recruiting | ITA | DEU | CAN | 3 |
NCT04787042 | Phase Ib/II | ST-067 | Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067 | Recruiting | USA | 0 |
NCT04802174 | Phase Ib/II | Berzosertib + Lurbinectedin | A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers | Recruiting | USA | 0 |
NCT04826341 | Phase Ib/II | Berzosertib + Sacituzumab govitecan-hziy | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | Recruiting | USA | 0 |
NCT04827576 | Phase II | Docetaxel + Hu5F9-G4 | Study of Magrolimab in Participants With Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 1 |
NCT04834778 | Phase I | HC-5404-FU | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | Recruiting | USA | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies | Recruiting | CAN | 0 |
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04870112 | Phase Ib/II | Carboplatin + Cisplatin + Durvalumab + Etoposide Durvalumab | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1) | Active, not recruiting | USA | ESP | 2 |
NCT04885998 | Phase I | AMG 404 + AMG 757 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | Active, not recruiting | USA | BEL | AUT | 3 |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Recruiting | USA | 0 |
NCT04919382 | Phase II | Atezolizumab + Temozolomide | Temozolomide and Atezolizumab as Second Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04923776 | Phase II | Atezolizumab + Carboplatin + Etoposide | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | Recruiting | USA | 0 |
NCT04924101 | Phase II | Cisplatin + Etoposide + Lenvatinib + Pembrolizumab Carboplatin + Etoposide + MK-5890 + Pembrolizumab Carboplatin + Etoposide + Lenvatinib + Pembrolizumab Carboplatin + Etoposide + MK-4830 + Pembrolizumab Cisplatin + Etoposide + MK-5890 + Pembrolizumab Cisplatin + Etoposide + MK-4830 + Pembrolizumab | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | Active, not recruiting | USA | ITA | ESP | CAN | AUT | 6 |
NCT04938817 | Phase Ib/II | Lenvatinib + MK-1308A MK-1308A MK-4280A MK-1308A + MK-4830 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | Active, not recruiting | USA | ITA | ESP | CAN | AUT | AUS | 6 |
NCT04951115 | Phase II | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04952597 | Phase II | Tislelizumab BGBA1217 + Tislelizumab | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 2 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | 0 |
NCT05027867 | Phase II | KRT-232 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Recruiting | USA | FRA | ESP | DEU | 1 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05060016 | Phase II | AMG 757 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 10 |
NCT05068232 | Phase II | Carboplatin + Durvalumab + Etoposide Durvalumab | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | Recruiting | USA | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05091567 | Phase III | Atezolizumab + Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide + Lurbinectedin | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte) | Recruiting | USA | ITA | GBR | ESP | DEU | BEL | 7 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05142696 | Phase I | Carboplatin + Etoposide + lutetium Lu 177 dotatate + Tislelizumab | A Safety Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients in Combination With Carboplatin, Etoposide and Tislelizumab | Recruiting | USA | FRA | ESP | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05161533 | Phase II | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | Recruiting | USA | 0 |
NCT05191797 | Phase Ib/II | Atezolizumab + IMG-7289 | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Recruiting | USA | CAN | 0 |
NCT05224141 | Phase III | Carboplatin + Etoposide + MK-7684A Cisplatin + Etoposide + MK-7684A Atezolizumab + Cisplatin + Etoposide Atezolizumab + Carboplatin + Etoposide | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 16 |
NCT05268666 | Phase Ib/II | JBI-802 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05271292 | Phase Ib/II | Chiauranib | Chiauranib for Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Recruiting | USA | 0 |
NCT05280470 | Phase II | DS-7300a | DS-7300a in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Active, not recruiting | USA | FRA | ESP | 4 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Recruiting | USA | 0 |
NCT05353257 | Phase III | Cisplatin + Etoposide + Serplulimab Carboplatin + Etoposide + Serplulimab | A Study to Evaluate the Efficacy and Safety of HLX10 in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer | Recruiting | USA | AUT | 2 |
NCT05353439 | Phase I | Pembrolizumab + Tazemetostat + Topotecan | Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05361395 | Phase I | AMG 757 + Atezolizumab AMG 757 + Atezolizumab + Carboplatin + Etoposide | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 7 |
NCT05363280 | Phase II | AL8326 | AL8326 in SCLC Treatment | Recruiting | USA | 0 |
NCT05384015 | Phase II | Carboplatin + Etoposide + Lenvatinib + Pembrolizumab | Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (PEERS) | Recruiting | ESP | 0 |
NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05403723 | Phase I | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | Recruiting | USA | 0 |
NCT05420636 | Phase II | ORY-1001 + Paclitaxel | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | Recruiting | USA | 0 |
NCT05438329 | Phase Ib/II | DB-1305 | First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05450965 | Phase II | Onvansertib | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05468489 | Phase III | Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide + Serplulimab | To Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC | Recruiting | USA | 0 |
NCT05546268 | Phase Ib/II | MRT-2359 | Study of Oral MRT-2359 in Selected Cancer Patients | Recruiting | USA | 0 |
NCT05572476 | Phase II | Durvalumab + Lurbinectedin Carboplatin + Etoposide | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (LURBIMUNE) | Not yet recruiting | FRA | 0 |
NCT05578326 | Phase II | Lurbinectedin + Trilaciclib | Study of Trilaciclib and Lurbinectidin | Recruiting | USA | 0 |
NCT05588388 | Phase II | Bevacizumab | Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases (BELIEVE) | Not yet recruiting | USA | 0 |
NCT05595460 | Phase I | Atezolizumab + Carboplatin + Etoposide + RYZ101 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | Recruiting | USA | 0 |
NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05617963 | Phase II | Durvalumab | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (DURVALUNG) | Recruiting | FRA | 0 |
NCT05619744 | Phase I | RO7616789 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Recruiting | USA | 1 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Recruiting | ESP | BEL | 0 |
NCT05620342 | Phase I | iC9.GD2.CAR.IL-15 T-cells | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | Not yet recruiting | USA | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05623319 | Phase II | Cisplatin + Etoposide + Pembrolizumab Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR) | Recruiting | ITA | 0 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05655598 | Phase I | Palbociclib + Pimitespib | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Not yet recruiting | USA | 0 |
NCT05700721 | Phase II | Dostarlimab-gxly + Niraparib | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | Not yet recruiting | USA | 0 |
NCT05703997 | Phase II | Atezolizumab | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction (FASTIMMUNE) | Not yet recruiting | ITA | 0 |
NCT05718323 | Phase II | Niraparib | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE) | Not yet recruiting | ITA | FRA | ESP | 1 |
NCT05815160 | Phase I | Carboplatin + Debio 0123 + Etoposide | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | Recruiting | ESP | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advance Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05856695 | Phase II | Carboplatin + Durvalumab + Paclitaxel | A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) (TAXIO) | Not yet recruiting | FRA | 1 |